

Sarcoma Cancer

**A study to look at the effectiveness of chemotherapy plus bevacizumab compared with chemotherapy alone in children and adolescents with metastatic soft tissue sarcoma (STS) (BERNIE)**

A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.

**Trial Status**  
Completed

**Trial Runs In**  
14 Countries

**Trial Identifier**  
NCT00643565 2007-005017-19  
BO20924

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This open-label two-arm study will assess the safety and efficacy of a combination of bevacizumab + standard chemotherapy with standard chemotherapy alone as active comparator in childhood and adolescent patients with metastatic rhabdomyosarcoma or non-rhabdomyosarcoma soft tissue sarcoma. Patients will be randomized to receive bevacizumab + standard chemotherapy or standard chemotherapy alone. Treatment will consist of 9 x 3-week cycles of induction treatment (standard chemotherapy with or without bevacizumab 7.5 mg/kg iv on day 1 of each cycle) followed by 12 x 4-week cycles of maintenance treatment (standard chemotherapy with or without bevacizumab 5 mg/kg iv on days 1 and 15 of each cycle). The anticipated time on study treatment is 1-2 years.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT00643565 2007-005017-19 BO20924**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥6 Months & ≤ 18 Years

**Healthy Volunteers**  
No

---